Related by context. Frequent words. (Click for all words.) 65 neuropsychiatric symptoms 61 T2DM 60 RRMS patients 60 glitazones 59 antiepileptic drug 58 antihypertensive medications 58 lipid lowering therapy 58 pramlintide 57 calcium supplementation 57 severe renal impairment 57 placebo controlled clinical 57 angiotensin receptor blockers 57 tocilizumab 57 lipid profiles 57 lipid lowering drugs 57 antihypertensive agents 57 antiplatelet agents 57 genetic polymorphisms 57 antihypertensive drugs 57 aripiprazole 57 QTc 57 HRQOL 56 comorbid conditions 56 multivariate analyzes 56 PsA 56 irbesartan 56 REMICADE ® 56 lactic acidosis 56 lamotrigine 56 left ventricular dysfunction 56 platelet inhibition 56 QT prolongation 56 affective disorders 56 hypercalcemia 56 confounding variables 56 hyperparathyroidism 56 acamprosate 56 nonadherence 56 cholinesterase inhibitors 55 citalopram 55 hepatotoxicity 55 hypocalcemia 55 androgen deprivation 55 N acetylcysteine 55 microalbuminuria 55 hyperglycaemia 55 QTc interval 55 T2D 55 ziprasidone 55 fasting glucose levels 55 Major Depressive Disorder 55 hypoglycemic events 55 LUTS 55 lipid levels 55 Mild Cognitive Impairment 55 montelukast 55 anticholinergics 55 Topiramate 55 placebo controlled clinical trials 55 cardiac toxicity 55 NAFLD 55 Pioglitazone 55 PREZISTA r 55 thrombotic events 55 hsCRP 55 alcoholic fatty liver 55 serum uric acid 55 cerebrovascular events 55 donepezil 55 asthma exacerbations 55 COPD exacerbations 55 obese adolescents 54 haematological 54 subgroup analyzes 54 COPAXONE R 54 tricyclic antidepressants 54 malignant pleural mesothelioma 54 candesartan 54 placebo controlled studies 54 thromboembolic events 54 renal impairment 54 colorectal cancer CRC 54 INVEGA 54 platelet function 54 systemic lupus erythematosus SLE 54 attention-deficit/hyperactivity disorder ADHD 54 renal insufficiency 54 chronic pancreatitis 54 omalizumab 54 stimulant medications 54 elevated triglycerides 54 CYP#D# 54 metabolic acidosis 54 vasomotor symptoms 54 lacosamide 54 thyroid dysfunction 54 hypertensive patients 54 cardiometabolic risk 54 secondary hyperparathyroidism 54 adalimumab 54 nasal obstruction